Final overall survival results from the PAPILLON trial show that adding amivantamab to chemotherapy extends median overall survival to 34.3 months for patients with a rare form of non-small cell lung cancer, representing the longest survival reported to date for this specific mutation.
PAPILLON Trial Results Confirm Survival Gains in Rare Lung Cancer
Medical researchers have released the final overall survival analysis from the landmark PAPILLON phase III clinical trial, offering new data for patients with a difficult-to-treat and rare form of lung cancer. The findings were presented by Chul Kim of Georgetown University’s Lombardi Comprehensive Cancer Center as part of a Presidential plenary at the 2026 World Conference on Lung Cancer in Seoul, South Korea.
Historically, median overall survival for this patient population hovered between 1.5 and 2 years. The final trial data push that figure significantly higher. Amivantamab plus chemotherapy extended overall survival to 34.3 months, nearly three years, compared to 27.9 months for chemotherapy alone.
“These new findings are meaningful because they represent what we believe is the longest median overall survival reported for people with this form of lung cancer. Historically, median overall survival in this patient population was about 1.5 to 2 years. In this trial, it reached 34.3 months-nearly 3 years.”
Chul Kim, MD, MPH, associate professor of medicine at Georgetown University School of Medicine and director of thoracic oncology at MedStar Georgetown University Hospital, via news-medical.net
Understanding the Target Population and Genetic Testing
The trial focused specifically on non-small cell lung cancers carrying an uncommon genetic alteration known as an EGFR exon 20 insertion mutation. While advanced forms of this mutation affect roughly 1% to 2% of all non-small cell lung cancer cases, they account for 5% to 10% of all EGFR-mutated instances, translating to roughly 1,500 to 2,500 diagnoses annually in the United States.
Identifying these rare alterations requires advanced diagnostic tools. Investigators noted that next-generation sequencing plays a vital role in matching patients with therapies specifically designed for their tumors. Amivantamab operates as a bispecific antibody, a targeted therapy engineered to bind to two separate biological targets simultaneously.
Accounting for Treatment Crossover in Survival Data
While the progression-free survival benefit was clear—cutting the risk of disease progression by 60 percent with an 11.4-month duration compared to 6.7 months for control groups—the final overall survival analysis did not reach formal statistical significance.
Researchers attributed this primarily to substantial crossover within the study design. Approximately three-quarters of eligible patients initially assigned exclusively to the control chemotherapy arm subsequently received amivantamab after their disease progressed. When adjusted for this crossover effect, the overall survival benefit becomes much more pronounced, reinforcing the combination as a foundational first-line therapy.
Broader Research Links Structured Exercise to Extended Cancer Survival
Away from targeted drug therapies, separate research published in the British Journal of Sports Medicine highlights how lifestyle interventions impact cancer outcomes. A comprehensive review conducted by specialists in Taiwan examined 21 separate trials across Asia, Australia, Europe, and North America involving more than 8,400 individuals.
Patients who integrated structured physical activity regimens into standard medical care faced a 23 per cent lower risk of mortality and were 17 per cent less likely to experience a cancer recurrence before death. Furthermore, these individuals demonstrated a 26 per cent reduced risk of dying specifically from cancer.
Defining Safe Physical Activity Interventions for Recovery
Researchers noted that the positive association was most pronounced among individuals who achieved a minimum 70 per cent completion rate of their assigned programs. Programs combining aerobic routines alongside resistance exercises yielded positive results, whereas resistance training on its own showed no significant effect, likely due to distinct biological adaptations.
Physical activity does not need to be strenuous to generate positive outcomes. Walking, gardening, and gentle movement all contribute to managing tiredness and supporting mental wellbeing during recovery.
“Being active doesn’t have to mean going to the gym or doing something strenuous. Walking, gardening or gentle movement can all count, and even small amounts of activity can make a difference. Everyone’s experience of cancer is different, so it’s important to find something that feels manageable and right for you.”
Claire Taylor, chief nursing officer at Macmillan Cancer Support, via Yahoo News Canada
Clinical teams continue to study amivantamab-based strategies in atypical EGFR-mutant non-small cell lung cancer as well as other tumor types, including head and neck and colorectal cancers, while public health organizations maintain a focus on individual consultation to determine safe activity thresholds for patients recovering from the disease.